2025
Does Stapling Platform Influence Robotic Sleeve Gastrectomy Postoperative Outcomes?
Ying L, Rutledge R, Butensky S, Lugo D, Morton J, Ringold F. Does Stapling Platform Influence Robotic Sleeve Gastrectomy Postoperative Outcomes? Obesity Surgery 2025, 35: 1838-1844. PMID: 40227538, PMCID: PMC12065732, DOI: 10.1007/s11695-025-07855-z.Peer-Reviewed Original ResearchConceptsGastroesophageal reflux diseasePostoperative outcomesNo significant differenceSleeve gastrectomyRate of de novo GERDStapler useOverall side effect profileRetrospective single-surgeon studyLinear staplerPostoperative refluxOperative timePostoperative length of stayBackgroundLaparoscopic sleeve gastrectomyPostoperative gastroesophageal reflux diseaseRate of postoperative refluxSingle-surgeon studySide effect profileSignificant differenceWeight lossWeight loss surgeryRobotic-assisted sleeve gastrectomyLength of stayPostoperative lengthPatient demographicsEffect profileA narrative review on multimodal spinal anesthesia: Old technique and new use
Pierson D, Certoma R, Hobbs J, Cong X, Li J. A narrative review on multimodal spinal anesthesia: Old technique and new use. Journal Of Anesthesia And Translational Medicine 2025, 4: 25-32. PMID: 40321954, PMCID: PMC12048027, DOI: 10.1016/j.jatmed.2025.02.002.Peer-Reviewed Original ResearchEffectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis
Sannaa W, Almasry M, Peedikayil M, Grimshaw A, Attamimi M, AlMutairdi A, Al-Bawardy B. Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therapeutic Advances In Gastroenterology 2025, 18: 17562848241312766. PMID: 39802627, PMCID: PMC11719443, DOI: 10.1177/17562848241312766.Peer-Reviewed Original ResearchOral vancomycin therapyPrimary sclerosing cholangitisIBD-PSCInflammatory bowel diseasePooled analysisClinical responseSclerosing cholangitisEpisodes of acute cholangitisFavorable side effect profilePooled analysis of studiesSystematic reviewInflammatory bowel disease associated with primary sclerosing cholangitisSide effect profileLong-term safetyClinical response/remissionVancomycin therapyOral vancomycinClinical remissionEndoscopic remissionAcute cholangitisMedian durationImmunosuppressive agentsNo episodesConcomitant treatmentEffect profile
2024
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do A, Zahrawi F, Mehal W. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nature Reviews Drug Discovery 2024, 24: 171-189. PMID: 39609545, DOI: 10.1038/s41573-024-01084-2.Peer-Reviewed Original ResearchSide effect profileTrial end pointsCombination of therapeuticsReverse many aspectsFatty acid synthase inhibitorGenetic susceptibility factorsPlacebo responseEffect profileFibrosis reversalTreated patientsClinical studiesLiver inflammationSynthase inhibitorLiver diseaseTherapeutic approachesClinical useEnd pointsSteatotic liver diseaseTherapeutic landscapeMetabolic environmentHepatocyte deathSusceptibility factorsChronic overnutritionGlobal epidemicLiverChallenges in management of older patients with chronic myeloid leukemia
Stempel J, Shallis R, Wong R, Podoltsev N. Challenges in management of older patients with chronic myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1219-1232. PMID: 38652861, DOI: 10.1080/10428194.2024.2342559.Peer-Reviewed Original ResearchChronic myeloid leukemiaTyrosine kinase inhibitorsTreatment-free remissionOlder patientsMyeloid leukemiaTyrosine kinase inhibitor dosingGeneration tyrosine kinase inhibitorsManagement of older patientsSecond-line agentsSurvival of patientsSide effect profileFront-line optionPrevalence of comorbiditiesImproved survivalCardiovascular toleranceEffect profileFavorable outcomeKinase inhibitorsPrevent progressionPatientsPersonalized treatmentQuality of lifeTreatment goalsOptimal careDiscontinuation strategies
2023
Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions
Zubair A, Rethana M, Ma A, McAlpine L, Abulaban A, Munro B, Patwa H, Nowak R, Roy B. Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions. Journal Of Clinical Neuromuscular Disease 2023, 25: 11-17. PMID: 37611265, DOI: 10.1097/cnd.0000000000000439.Peer-Reviewed Original ResearchConceptsNeuro-immunological diseaseIntravenous immunoglobulinAutoimmune neurological disordersAutoimmune neuromuscular disorderAdult patientsElderly patientsNeurological disordersNeuromuscular disordersChronic inflammatory demyelinating polyradiculoneuropathyNational Inpatient Sample databaseNational Inpatient Sample datasetInflammatory demyelinating polyradiculoneuropathySafe therapeutic choiceRetrospective chart reviewAppropriate clinical settingSide effect profileDemyelinating polyradiculoneuropathyIVIG useChart reviewYounger patientsMyasthenia gravisEffect profileMedical historyPrimary diagnosisTherapeutic choiceEfficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials
Le G, Gillissie E, Rhee T, Cao B, Alnefeesi Y, Guo Z, Di Vincenzo J, Jawad M, March A, Ramachandra R, Lui L, McIntyre R. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials. Expert Opinion On Investigational Drugs 2023, 32: 401-415. PMID: 37096491, DOI: 10.1080/13543784.2023.2206559.Peer-Reviewed Original ResearchConceptsTrace amine-associated receptor 1Long-term efficacyTreatment of schizophreniaClinical trialsSystematic reviewMental disordersNegative symptomsAdverse effectsAdverse effect profileCochrane Collaboration's toolRisk of biasInclusion/exclusion criteriaNovel therapeutic targetPubMed/MEDLINEQuality of lifeMechanism of actionAlternative treatment methodAtypical antipsychoticsEffect profileSimilar pathophysiologyCognitive dysfunctionPreclinical studiesExclusion criteriaOvid databasesTherapeutic targetPharmacological effects of methylone and MDMA in humans
Poyatos L, Pérez-Mañá C, Hladun O, Núñez-Montero M, de la Rosa G, Martín S, Barriocanal A, Carabias L, Kelmendi B, Taoussi O, Busardò F, Fonseca F, Torrens M, Pichini S, Farré M, Papaseit E. Pharmacological effects of methylone and MDMA in humans. Frontiers In Pharmacology 2023, 14: 1122861. PMID: 36873994, PMCID: PMC9981643, DOI: 10.3389/fphar.2023.1122861.Peer-Reviewed Original ResearchAddiction Research Center InventoryVisual analog scaleSubjective effectsClinical trialsPharmacological effectsAbuse potentialAcute pharmacological effectsCrossover clinical trialSingle oral doseMechanism of actionBlood pressureEffect profileOral doseAnalog scaleOral administrationHeart ratePrevious historyPsychostimulant usePsychomotor performanceOverall onsetPleasurable effectsMDMAPhysiological effectsShort formEarly disappearance
2022
Polycystic Kidney Disease Drug Development: A Conference Report
Liebau M, Mekahli D, Perrone R, Soyfer B, Fedeles S. Polycystic Kidney Disease Drug Development: A Conference Report. Kidney Medicine 2022, 5: 100596. PMID: 36698747, PMCID: PMC9867973, DOI: 10.1016/j.xkme.2022.100596.Peer-Reviewed Original ResearchAutosomal dominant polycystic kidney diseasePolycystic kidney diseaseAutosomal recessive polycystic kidney diseaseRecessive polycystic kidney diseaseKidney diseaseProgression of ADPKDSide effect profileChronic kidney failureDisease-modifying therapiesAutosomal dominant polycystic liver diseasePolycystic liver diseaseTotal kidney volumeDominant polycystic kidney diseaseCritical Path InstituteMechanism of actionCommon monogenic disorderDrug development toolsEffect profileLiver diseaseKidney failureOutcomes ConsortiumEnrichment biomarkerClinical trialsKidney volumeSurrogate endpointsEfficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode
Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode. JAMA Psychiatry 2022, 79: 1162-1172. PMID: 36260324, PMCID: PMC9582972, DOI: 10.1001/jamapsychiatry.2022.3352.Peer-Reviewed Original ResearchConceptsStandardized mean differenceMajor depressive episodeSerious adverse eventsElectroconvulsive therapyAdverse eventsDepressive episodeClinical trialsDepression severityEfficacy outcomesSystematic reviewUnique adverse effect profileMeta-analyses (PRISMA) reporting guidelinesSafety of ketamineAdverse effect profileData extractionEuropean clinical trialsDiagnosis of depressionModerate methodological qualityMedical Subject Headings termsPreferred Reporting ItemsCognition/memoryRandom-effects modelSubject Headings termsAcute phaseEffect profileOverall Infectious Complications Related to Belatacept Conversion in Comparison to Tacrolimus in Kidney Transplant Recipients
Marvin JE, Azar MM, Belfield KD, Do V, Formica R, Cohen EA. Overall Infectious Complications Related to Belatacept Conversion in Comparison to Tacrolimus in Kidney Transplant Recipients. Progress In Transplantation 2022, 32: 351-356. PMID: 36039533, DOI: 10.1177/15269248221122894.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsProportion of patientsBelatacept conversionInfectious complicationsTransplant recipientsExact testLong-term infectious complicationsFavorable side effect profileOverall infectious complicationsSide effect profileTime of transplantFisher's exact testT-testStudent's t-testMann-Whitney UInduction immunosuppressionTacrolimus patientsKidney transplantMore patientsPrimary outcomeEffect profileTacrolimusOutcome dataHigh incidenceRetrospective evaluationIncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial
Kohli N, Lerner M, Rashty J, Kirke D, Stewart T, Blitzer A. IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial. American Journal Of Otolaryngology 2022, 43: 103613. PMID: 36055061, DOI: 10.1016/j.amjoto.2022.103613.Peer-Reviewed Original ResearchConceptsAdductor spasmodic dysphoniaSpasmodic dysphoniaOpen-label clinical trialProspective open-label trialAdductor laryngeal dystoniaOpen-label trialFirst-line treatmentVoice Handicap Index-10Side effect profileTransient side effectsNormal functionVHI-10 scoresIncobotulinumtoxinA injectionsEffect profileLine treatmentSystemic diseaseTA muscleBotulinum toxinClinical trialsLaryngeal dystoniaNursing womenThyroarytenoid muscleInjection sessionsExclusion criteriaSide effectsComplementary and integrative medicine perspectives among veteran patients and VHA healthcare providers for the treatment of headache disorders: a qualitative study
Kuruvilla DE, Lindsey H, Grinberg AS, Goldman RE, Riley S, Baird S, Fenton BT, Sico JJ, Damush TM. Complementary and integrative medicine perspectives among veteran patients and VHA healthcare providers for the treatment of headache disorders: a qualitative study. BMC Complementary Medicine And Therapies 2022, 22: 22. PMID: 35078450, PMCID: PMC8790919, DOI: 10.1186/s12906-022-03511-6.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationVeteran patientsHeadache managementClinical providersBackgroundThe Veterans Health AdministrationFavorable adverse effect profileVHA healthcare providersAdverse effect profileManagement of veteransChronic headache managementCIM modalitiesWhole health systemEffect profileHeadache centerChronic headacheHeadache disordersPatients' perceptionsHeadache treatmentSafe additionPatientsTreatment efficacyIntegrative medicineHealth AdministrationProviders' perceptionsHealthcare providersEnhanced Recovery After Surgery: Opioid Sparing Strategies After Discharge: A Review
Rajput K, Shergill S, Chow RM, Vadivelu N, Kaye AD. Enhanced Recovery After Surgery: Opioid Sparing Strategies After Discharge: A Review. Current Pain And Headache Reports 2022, 26: 93-102. PMID: 35072920, DOI: 10.1007/s11916-022-01009-x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsOpioid usePersistent post-surgical painNon-opioid strategiesNon-opioid therapiesOpioid-sparing strategiesOverprescribing of opioidsPostoperative pain scoresMultimodal analgesic approachPost-surgical painSide effect profileNon-opioid analgesicsRecent FindingsSeveral studiesERAS protocolOpioid protocolAnalgesic approachBreakthrough painHospital stayMultimodal analgesiaPain scoresAcute painOral ketaminePostoperative periodEffect profilePatient recoveryGood quality researchMedical Therapy with Antimuscarinics and ß3-Agonists
Goodridge S, Rickey L. Medical Therapy with Antimuscarinics and ß3-Agonists. 2022, 147-164. DOI: 10.1007/978-3-030-84352-6_8.Peer-Reviewed Original ResearchOveractive bladderManagement of OABTreatment of OABMedical therapy optionsSecond-line therapyFirst-line treatmentSide effect profileBeta-3 agonistQuality of lifeMedical therapyEffect profileTherapy optionsDrug classesComparative efficacyBehavioral modificationAntimuscarinicsBladderTherapyEfficacyTreatmentPharmacotherapyPatientsAgonistsLarge subsetProgression
2021
An Overview of Anxiety, Trauma-Related and Obsessive-Compulsive Disorders
Conroy M, van Dyck L, Lane C, Cook J. An Overview of Anxiety, Trauma-Related and Obsessive-Compulsive Disorders. Current Geriatrics Reports 2021, 10: 91-100. DOI: 10.1007/s13670-021-00361-x.Peer-Reviewed Original ResearchObsessive-compulsive disorderOlder adultsOverview of anxietyPurpose of ReviewAnxietyPsychosocial interventionsMental health conditionsPsychosocial consequencesMental health specialistsAnxietyOlder patientsPsychiatric disordersInappropriate medication useFirst-line treatmentSide effect profilePrimary care settingSymptomatologyDisordersAdultsAmerican Geriatrics SocietyHealth specialistsBeers criteriaMedication useEffect profilePharmacological treatmentPatient symptomatologyEtonogestrel contraceptive implant uptake and safety among solid organ transplant recipients
Lew J, Sheeder J, Lazorwitz A. Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients. Contraception 2021, 104: 556-560. PMID: 34147509, PMCID: PMC8502202, DOI: 10.1016/j.contraception.2021.06.007.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOrgan transplant recipientsReproductive-age womenEtonogestrel contraceptive implantContraceptive implant usersTransplant recipientsContraceptive implantsCommon transplant-related complicationPost-transplant infectionsSafe contraceptive optionTransplant-related outcomesRetrospective cohort studyTransplant-related complicationsGraft-related complicationsSide effect profileTertiary medical centerRisk of pregnancyImplant usersContraceptive implant useAdditional health risksPregnancy patternsCohort studyGraft complicationsGraft rejectionEffect profileNon-steroidal treatment of cardiac sarcoidosis: A systematic review
Gallegos C, Oikonomou EK, Grimshaw A, Gulati M, Young BD, Miller EJ. Non-steroidal treatment of cardiac sarcoidosis: A systematic review. IJC Heart & Vasculature 2021, 34: 100782. PMID: 33997256, PMCID: PMC8105294, DOI: 10.1016/j.ijcha.2021.100782.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNon-steroidal treatmentSteroid-sparing agentCardiac sarcoidosisSafety profileSystematic reviewCases of CSDisease-modifying antirheumatic agentsManagement of CSActive cardiac sarcoidosisAnti-inflammatory managementAverage corticosteroid doseHigher-line treatmentsMaintenance steroid doseFirst-line treatmentSide effect profileSteroid-sparing therapiesInception of databasesLong-term useCorticosteroid doseSteroid doseBiologic DMARDsImmunosuppressive therapyTreatment initiationEffect profileImmunosuppressive agentsRethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options.
Escobar CM, Falk KN, Mehta S, Hall EF, Menhaji K, Sappenfield EC, Brown OE, Ringel NE, Chang OH, Tellechea LM, Barnes HC, Jeney SES, Bennett AT, Cardenas-Trowers OO. Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options. Obstetrics And Gynecology 2021, 137: 454-460. PMID: 33543891, DOI: 10.1097/aog.0000000000004279.Commentaries, Editorials and LettersConceptsOveractive bladderΒ3-adrenoceptor agonistHealth care inequalitiesOral medicationsFavorable side effect profileTreatment of OABAlternative oral treatmentSecond-line therapySide effect profileCare inequalitiesIdiopathic overactive bladderCognitive side effectsHealth care professionalsQuality of lifeProcedural therapiesOral treatmentEffect profileOAB medicationsTreatment algorithmTreatment optionsChronic conditionsCare professionalsSide effectsMedicationsBetter careNovel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer
Mauricio D, Harold J, Tymon-Rosario JR, Zeybek B, Santin AD. Novel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer. Expert Opinion On Biological Therapy 2021, 21: 1087-1096. PMID: 33356644, DOI: 10.1080/14712598.2021.1869210.Peer-Reviewed Original ResearchConceptsAntibody-drug conjugatesOvarian cancerProgressive diseaseFavorable adverse effect profilePromising novel therapeutic agentAdverse effect profilePhase II trialDeadliest gynecologic malignancyPhase III dataNovel therapeutic agentsII trialGynecologic malignanciesEffect profileClinical resultsEffective therapyAvailable agentsCurrent evidenceNovel treatmentsChemotherapeutic agentsCancerTherapeutic agentsAdverse effectsMesothelinVivo dataDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply